It was a pleasure to meet with José A. López García (University of Alcalá, Alcalá de Henares, Spain) to discuss the clinical development of SAN711, a selective GABAA α3 receptor positive allosteric modulator for the potential treatment of neuropathic pain.
The abstract entitled: ‘SAN711 a selective GABAA α3 receptor positive allosteric modulator as a novel treatment for trigeminal neuralgia ’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
Questions:
- Could you tell us a little about SAN711, its selectivity and mechanism of action? (0:16)
- What are the objectives and design of the Phase 1 study of SAN711? (8:53)
- What are the intended clinical indications of SAN711? (10:55)
Disclosures: José A. López García has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021
